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I
n wealthy countries, state-funded research has yielded 
breakthroughs in molecular biology, chemistry, and 
engineering. These advances have been taken up by the 
pharmaceutical industry and applied to drug development 
for a growing range of illnesses and conditions. As a result, 
patients have access to new drugs that are better tolerated, 
more speciﬁ  c, and more effective than old ones. 
In poor countries, however, millions of people have yet 
to experience the beneﬁ  ts wrought by science. The deadly 
infectious diseases that plague them, such as sleeping 
sickness, Chagas disease, and visceral leishmaniasis, fail to 
arouse the interest of drug developers.
The Drugs for Neglected Diseases Initiative (DNDi) is a 
new, not-for-proﬁ  t organisation set up to correct this fatal 
imbalance by developing new drugs for these forgotten 
patients. 
Dropped off the Radar Screen
Most of the drugs still used to treat ‘neglected diseases’ were 
developed in colonial times. These are often expensive, 
difﬁ  cult to administer, and hard to tolerate; several of them 
are also becoming ineffective because of increasing parasite 
resistance. Very few new alternatives have been developed in 
the past decades: between 1975 and 1999, 1,393 new drugs 
were made available to the public, but only 16 of these were 
meant for neglected diseases [1].
What makes the lack of drugs more difﬁ  cult to accept 
is that scientists know an enormous amount about 
kinetoplastids, the organisms responsible for sleeping 
sickness, Chagas disease, and leishmaniasis [2]. The wealth 
of knowledge generated in this ﬁ  eld could easily be used for 
drug development if the treatment of neglected diseases were 
perceived as ﬁ  nancially attractive. But populations affected by 
neglected diseases have no purchasing power, so there is no 
ﬁ  nancial incentive for drug companies to develop the drugs. 
The basic mechanics of the market-driven system are failing 
to help these populations. So most scientiﬁ  c research stops 
at the publication stage or falls through the gaps at different 
stages of the drug development pipeline (Figure 1) [3].
Whose Role Is It, Anyway? 
It is dangerous to oversimplify the causes of this situation. 
What share of responsibility for the world’s health is borne 
by the pharmaceutical industry, which has the know-how 
and the resources for innovation? Aren’t international 
organisations also partly responsible? After all, they are the 
ones who allocate major funding for health programmes and 
encourage research programmes. And what about public 
research institutions in rich countries that generate the 
knowledge used by industry? Governments have the power 
to inﬂ  uence their research priorities and drug development 
decisions, either through funding or direct involvement. 
Unfortunately drugs for neglected diseases are low priority 
for governments [4]. They tend to prioritise research with 
potential commercial applications instead.
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Responses to the Crisis
All is not doom and gloom. In the past few years, there 
has been some movement on research and development 
(R&D) for neglected diseases. Despite its broad mandate 
and limited resources, the Special Programme for Research 
and Training in Tropical Diseases (TDR)—established and 
funded by the World Health Organization, the World Bank, 
and the United Nations Development Programme—can 
be credited with several important successes in the ﬁ  ght 
against malaria and leishmaniasis. The Medicines for Malaria 
Venture and the Global Alliance for TB Drug Development 
were set up as public–private partnerships to tackle malaria 
and tuberculosis. These partnerships were made possible 
by the fact that malaria and tuberculosis are global diseases, 
affecting patients in the North and South, so there was 
enough of a market to persuade industry to develop new 
drugs for these diseases. 
A different solution, however, was needed for diseases 
that are limited to tropical countries, are of no military or 
strategic interest to wealthy countries, and are not supported 
by markets or patients’ organisations capable of attracting 
the attention of politicians. This is the kind of solution put 
forward by the DNDi.
A Collaborative Not-for-Proﬁ  t
DNDi is a not-for-proﬁ  t organisation designed to mobilise 
resources for R&D of new drugs for neglected diseases. 
Many people and organisations around the world share an 
ambition to redress the lack of new treatments for neglected 
diseases, and bring the beneﬁ  ts of science to forgotten 
patients. Several of them came together to create DNDi: one 
humanitarian organisation—Médecins Sans Frontières; ﬁ  ve 
research institutions—the Oswaldo Cruz Foundation from 
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Medicines for Malaria Venture: http://www.mmv.orf
Global Alliance for TB Drug Development: 
http://www.tballiance.org
Oswaldo Cruz Foundation: http://www.ﬁ  ocruz.br
Indian Council for Medical Research: 
http://icmr.nic.in/home.htm
Kenya Medical Research Institute: http://www.kemri.org
Ministry of Health Malaysia: http://dph.gov.my/
Pasteur Institute: http://www.pasteur.fr/externe
Médecins Sans Frontières: http://www.msf.org
DOI: 10.1371/journal.pmed.0010006.g001
Figure 1. The Drug Development Pipeline
Because of the gaps in the development pipeline, potential new drugs for neglected diseases often stay stuck at an early stage of 
development.
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Brazil, the Indian Council for Medical Research, the Kenya 
Medical Research Institute, the Ministry of Health Malaysia, 
and the Pasteur Institute from France; and the TDR (Box 1). 
The initiative is a virtual organisation with a growing 
network of academic and R&D expertise at its disposal. The 
different players involved in DNDi are bringing their know-
how in parasitology and clinical trials, their experience 
treating neglected patients, and their drug manufacturing 
capacity.  They are pooling these resources to move drugs 
stuck in the pipeline all the way to the patients themselves. 
Pharmaceutical companies have a particularly important role 
to play: they possess vast repositories of molecules, the means 
to move from development to industrial production, and 
highly specialised teams of researchers. Their contribution 
will be crucial to the success of DNDi.
Matching Needs and Opportunities
DNDi is a needs-driven initiative—in other words, the needs 
of patients suffering from neglected diseases are paramount 
in its search for new drugs to treat them. The organisations 
that make up DNDi have ﬁ  rsthand knowledge of these 
needs because they work with patients in disease-endemic 
countries throughout the developing world. The initiative 
is taking this knowledge of patient needs, matching it with 
opportunities in R&D, and pushing the most relevant projects 
through the pipeline. Ultimately, neglected patients will 
have access to drugs targeting their speciﬁ  c diseases, drugs 
that were designed with them speciﬁ  cally in mind—such 
as short-course, low-toxicity treatments that don’t require 
hospitalisation, or tablets to swallow rather than injections. 
To identify opportunities in R&D that are both relevant 
to patient needs and that meet required criteria of scientiﬁ  c 
merit, DNDi is sending out calls for letters of interest to 
the scientiﬁ  c community via advertisements in journals and 
posted on the DNDi website (http:⁄⁄www.dndi.org). These 
have already pinpointed several promising projects. DNDi is 
also proactively contacting scientists working on infectious 
diseases, and surveying published literature for research of 
interest. 
In the Pipeline
DNDi’s project portfolio currently holds nine projects 
at different stages of development to address identiﬁ  ed 
needs for the treatment of visceral leishmaniasis, sleeping 
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Figure 2. DNDi Projects
DNDi’s project portfolio contains nine projects spread out across the drug development pipeline for the treatment of leishmaniasis, 
sleeping sickness, Chagas disease, and malaria. HAT, human African trypanosomiasis (sleeping sickness); VL, visceral leishmaniasis.
Box 2. New Drugs for Sleeping Sickness
Only a few drugs exist to treat sleeping sickness, and they 
are toxic or difﬁ  cult to administer. Melarsoprol kills one in 20 
patients. Eﬂ  ornithine requires four daily infusions over 14 days. 
Given these limited options, DNDi is focusing on identifying 
new compounds that can cross the blood–brain barrier to treat 
second stage sleeping sickness. 
DNDi is using high throughput screening on whole cell 
trypanosomes to discover novel lead compounds, and is working 
to identify and optimise inhibitors of the enzyme protein 
farnesyltransferase. The initiative is working on validating the 
kinetoplastid enzyme dihydrofolate reductase as a drug target. 
Identifying trypanothione inhibitors is also relevant to other 
trypanosome parasites. These are long term projects. 
Nifurtimox, a drug for Chagas disease, has been used to treat 
sleeping sickness since the 1970s in some isolated places. It 
has never been extended to more people because no one has 
studied its safety or effectiveness. DNDi will assess its short-
term usefulness by conducting clinical trials on a treatment 
combination of eﬂ  ornithine and nifurtimox. DNDi will continue 
to explore other short- and medium-term projects.PLoS Medicine  |  www.plosmedicine.org 022
sickness (Box 2), Chagas disease, and malaria (Figure 
2). At discovery stage, DNDi is working on validating 
the kinetoplastid enzyme dihydrofolate reductase as a 
potential target for leishmaniasis, trypanosomiasis, and 
Chagas disease, and on identifying inhibitors of the 
kinetoplastid enzymes trypanothione reductase and protein 
farnesyltransferase. It is also conducting high throughput 
screening on whole cell trypanosomes to discover novel lead 
compounds.
The R&D of new drugs is time-consuming and expensive 
if the process starts at the early discovery stage, because of 
the associated risk of project attrition along the way. DNDi 
is therefore investing resources in several pre-development 
and development projects as well. These include developing 
ﬁ  xed dose combinations of artesunate/amodiaquine 
and artesunate/meﬂ  oquine for use against chloroquine-
resistant malaria in Africa and Asia, respectively; pushing 
for registration of paromomycin for use against visceral 
leishmaniasis in Africa; assessing combinations of existing 
drugs for visceral leishmaniasis; and evaluating the usefulness 
of nifurtimox in combination with eﬂ  ornithine in the 
treatment of sleeping sickness.
Advocacy for Change
Governments can—some might say should—inﬂ  uence 
drug development choices. DNDi strongly believes that 
governments in both developed and developing countries 
should take an active interest in the R&D of new drugs for 
neglected diseases. In parallel to its own drug development 
activities, DNDi is working to raise awareness of the neglected 
disease crisis among key policy- and decision-makers, for 
instance the European Commission and the National 
Institutes for Health in the United States. 
Conclusion
In the poorer countries in the world, over 350 million people 
are at risk from neglected diseases. Currently available 
treatments are inadequate or nonexistent, and new solutions 
are urgently needed. DNDi is working to ensure that the 
advances of science that have brought health and comfort to 
wealthy nations also beneﬁ  t these neglected populations.  
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